These results suggested that CDKN1A and RAD21 were two direct target genes of miR-17 and miR-92 families and the high expressions of CDKN1A and RAD21 could combinedly promote the cisplatin resistance in NSCLC. The gene discussed is CDKN1A; the disease is non-small cell lung carcinoma.